Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07532252

Daridorexant for Alcohol Use Disorder

This study will test whether the dual orexin receptor antagonist (DORA) daridorexant reduces alcohol craving and use and improves total sleep time among patients with co-occurring alcohol use disorder and sleep disturbance. The study will assess the role of the orexin system in modulating alcohol craving and use in a real-world treatment setting.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Current moderate or severe DSM-5 criteria for AUD at the time of the screening session
  • Evidence of clinically significant sleep disturbance, based on the Pittsburgh Sleep Quality Index (PSQI; i.e., score >5)
  • Aged 18 years or older
  • Willingness to comply with all components of the study protocol
  • Use of birth control throughout the study, if a pre-menopausal female who is not sterile, and who is sexually active with a male partner or considering being sexually active with a male partner
  • Report ability to access a computer with an internet connection during the outpatient phase of the study to complete virtual outpatient visits
  • Report a desire to quit or reduce drinking (i.e., not enrolling in treatment solely to satisfy an external requirement)
  • Able to provide informed consent, and evidence an understanding of study procedures based on a quiz following informed consent
  • Fluent in English (in order to complete study assessments).

Exclusion criteria

  • Current moderate or severe substance use disorder other than AUD, cannabis use disorder, nicotine use disorder, or caffeine use disorder
  • Pregnant or breastfeeding, or planning to become pregnant during the study
  • Known allergy to any DORA
  • Past 30-day use of any DORA
  • Current use of benzodiazepines or other schedule IV medications for insomnia
  • Use of any medications that are contraindicated for use with daridorexant
  • Current withdrawal symptoms, as assessed by a score >8 on the Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-Ar) and benzodiazepine administration in the past 24 hours
  • Past-year suicidal behavior
  • Current bipolar disorder or psychotic disorder
  • Abnormal liver enzyme levels (i.e., AST or ALT greater than five times above the upper limit of normal, or bilirubin greater than two times the upper limit of normal), as assessed during standard intake procedures at Ashley Addiction Treatment
  • AHI>30, as assessed using a wireless EEG/apnea device, to rule out those with severe sleep apnea
  • Any other medical or psychological condition that is judged by the investigators to impede ability to safely complete study requirements
  • Legal problems or living situation judged by the investigators as a factor that could interfere with study completion (e.g., impending jail time).

Treatment and study plan

Daridorexant 50 mg

Drug

Daridorexant 50 mg (Orally administered)

Placebo

Other

Placebo (Oral)

Primary outcomes

  1. Total Sleep Time (Minutes)

    Time frame: Enrollment to one month follow-up

    Total sleep time will be assessed through both wireless EEG and ambulatory monitoring. Wireless EEG will be assessed during the residential phase only. Ambulatory monitoring will occur during both the residential and outpatient phase.

  2. Alcohol Craving Visual Analogue Scale

    Time frame: Enrollment to one month follow-up

    Visual Analogue Scales assessing alcohol craving will be administered (Range 0-100, higher scores indicate greater craving).

  3. Daily alcohol use, assessed via Timeline Followback (TLFB)

    Time frame: Outpatient phase (Day 1 post-residential treatment to one-month follow-up)

  4. Number of Adverse Events

    Time frame: From enrollment to one month follow-up

Secondary outcomes

  1. Daily binge drinking, assessed via Timeline Followback (TLFB)

    Time frame: Outpatient phase (Day 1 post-residential treatment to one-month follow-up)

  2. Number of Participants with Positive breathalyzer screen

    Time frame: Outpatient phase (Day 1 post-residential treatment to one-month follow-up)

  3. Number of Alcohol use disorder symptoms

    Time frame: Enrollment to one-month follow-up

    Alcohol use disorder symptoms, assessed using the Alcohol Use Disorders module of the Mini-International Neuropsychiatric Interview. 9-items rated on a dichotomous Yes/No scale.

  4. Self-Reported Insomnia Severity

    Time frame: Enrollment to one-month follow-up

    Self-reported insomnia severity, assessed using the Insomnia Severity Index. Each item is scored 0 (no problem) - 4 (very big problem) likert scale with total score range between 0-28 (absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).

Study contacts

Contact information is provided by the study sponsor or research team.

Jennifer Ellis

CONTACT

[email protected]

410-550-6346

Sponsors and collaborators

Lead sponsor

Johns Hopkins University

Other

Collaborators

  • Idorsia Pharmaceuticals Ltd.
  • National Institutes of Health (NIH)

Registry information

Official study title

A Double-Blind Randomized Controlled Trial of Daridorexant for Alcohol Use Disorder

Important dates

Study start
2027
Primary completion
2030
Study completion
2031
First posted
Apr 15, 2026
Registry last updated
Apr 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.